J. Chirgwin

发表

Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the SOLE Trial

P. Neven, A. Goldhirsch, G. Viale, 2020, Clinical Cancer Research.

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.

P. Neven, R. Gelber, A. Goldhirsch, 2018, The Lancet. Oncology.

The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause

A. Goldhirsch, M. Regan, A. Coates, 2011, Breast Cancer Research and Treatment.

Aromatase inhibitor induced musculoskeletal syndrome: a significant problem with limited treatment options

J. Forbes, N. Zdenkowski, J. Chirgwin, 2016, Supportive Care in Cancer.

Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: a clinical review.

J. Chirgwin, S. Chua, Jacquie Chirgwin, 2011, Breast.

Rational use of trastuzumab in metastatic and locally advanced breast cancer: implications of recent research.

S. Goel, P. Francis, L. Mileshkin, 2011, Breast.

Continuous vs intermittent extended adjuvant letrozole for breast cancer: Final results of randomized phase 3 SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.

P. Neven, S. Loi, S. Loibl, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

P. Neven, R. Gelber, H. Gómez, 2019, British Journal of Cancer.

Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.

J. Forbes, R. Gelber, R. Paridaens, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem).

J. Forbes, V. Gebski, P. Francis, 2014, Breast.

Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.

J. Forbes, R. Gelber, R. Paridaens, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Systemic treatment of HER2‐positive metastatic breast cancer: A systematic review

K. Pittman, P. Francis, R. Bell, 2014, Asia-Pacific Journal of Clinical Oncology.

The impact and indications for Oncotype DX on adjuvant treatment recommendations when third‐party funding is unavailable

B. Kiely, G. Mann, Y. Antill, 2018, Asia-Pacific journal of clinical oncology.

Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence.

A. Giobbie-Hurder, J. Forbes, P. Neven, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.

István Láng, A. Giobbie-Hurder, J. Forbes, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Systemic treatment of HER2+ metastatic breast cancer: Clinical conundrums and future perspectives

K. Pittman, P. Francis, R. Bell, 2014, Asia-Pacific journal of clinical oncology.

Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy

A. Giobbie-Hurder, R. Gelber, A. Goldhirsch, 2020, Breast Cancer Research and Treatment.

Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.

R. Gelber, H. Gómez, A. Goldhirsch, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

P. Neven, R. Gelber, H. Gómez, 2019, British Journal of Cancer.

Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial.

H. Wildiers, D. Richel, J. Canon, 2012, Annals of Oncology.

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

M. Lena, F. Peradotto, P. Koralewski, 2007 .